Navigation Links
National Organization for Rare Disorders Presents CSL Behring With 2011 Corporate Award
Date:5/17/2011

KING OF PRUSSIA, Pa., May 17, 2011 /PRNewswire/ -- CSL Behring, a global biotherapeutics company specializing in plasma-derived and recombinant therapies and a subsidiary of CSL Limited (ASX: CSL), is a recipient of the National Organization for Rare Disorders (NORD) 2011 Corporate Award. The award was presented this evening at the NORD Partners in Progress Celebration 2011 for "new treatments brought to market for patients with rare diseases."

(Logo: http://photos.prnewswire.com/prnh/20100914/PH63692LOGO)

CSL Behring's new treatment, factor XIII concentrate (human), is approved for the routine prophylactic treatment of congenital factor XIII deficiency, an extremely rare and potentially life-threatening bleeding disorder. Factor XIII concentrate (human) is the first and only dual sub-unit FXIII concentrate. It contains both A and B sub-units to treat FXIII patients regardless of sub-unit deficiency. Congenital factor XIII deficiency is estimated to affect one person in two million, with an incidence in the U.S. of approximately 150 people. (1)

"CSL Behring is honored to receive this NORD Corporate Award," said Paul Perreault, CSL Behring Executive Vice President for Worldwide Commercial Operations and incoming president. "People with rare diseases often face a host of challenges in being accurately diagnosed and in gaining ongoing access to appropriate medical care. CSL Behring focuses on these areas and partners with groups such as NORD to improve patients' lives. We commend NORD for their outstanding achievements and dedication to supporting people with rare diseases."

This award is the most recent in a series of recognitions for CSL Behring's innovative therapies used to treat rare and serious diseases. NORD previously honored CSL Behring for developing fibrinogen concentrate (human) for treating acute bleeding episodes in patients in the U.S. with congenital fibrinogen deficiency (CFD).

NORD is a leading patient advocacy organization whose mission is to advance the causes of people with rare diseases. They provide support for orphan product research – products used to treat serious conditions that affect fewer than 200,000 people – and they develop and advocate on public policy issues before Congress and health agencies.  

About CSL Behring

CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, immune thrombocytopenic purpura, burn treatment and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX:CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com.

(1) Greenberg C, Sane D, Lai Thung-Shen. Factor XIII and fibrin stabilization. In: Coleman R, Clowes A, Goldhaber S, Marder V, George J, ed. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2006; 325.  

Contact:
Chris Florentz
Manager Corporate Communications
CSL Behring
610-878-4316  
Christopher.Florentz@cslbehring.com


'/>"/>
SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Food Allergies Common among Children and Linked to Environmental Allergies and Asthma Later in Life, Suggests Largest-Ever National Allergy Study
2. SyntheZyme Wins Second National Science Foundation Grant to Commercialize Promising Biopesticide
3. Cynosure Receives Additional International Regulatory Approvals for New Cellulite Reduction Workstations
4. International Sales Agreement Signed by WNDM Subsidiary; $500K First-Year Sales Commitment
5. MedImmune To Present Eight Abstracts on Projects Regarding Thoracic and Respiratory Issues at the Annual American Thoracic Society International Conference
6. Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results
7. Cobalis Corp. Launches National Television Commercials for PreHistin® Allergy Defense Formula
8. Chindex International, Inc. Reports First Quarter 2011 Financial Results
9. Boston Scientific Begins U.S. and International Launch of Expect™ Endoscopic Ultrasound Aspiration Needle
10. Ferring Pharmaceuticals to Support Great Prostate Cancer Challenge® Events Across the Country in National Effort to End Prostate Cancer
11. Boston Scientific Begins International Launch and First Implants of Next-Generation Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Following receiving CE Marking in ... s AMAR is a major milestone for the country where the ... ound care market in Israel ... for inclusion in the National Health Basket , Israel ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment ...
(Date:2/24/2017)... and Markets has announced the addition of the "Dry eye Drugs ... ... Drugs Price Analysis and Strategies - 2016, provides drug pricing data and ... following questions: What are the key drugs ... in the Global Dry eye market? What are the ...
(Date:2/24/2017)... , Feb. 23, 2017 The ... of the PhenoTest BC Kit, performed on the ... identify organisms that cause bloodstream infections and provide ... to respond to (antibiotic sensitivity). The test also ... provide this important information, which can guide antibiotic ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... Much attention has been paid ... who become dependent on opioid painkillers has fallen short. From 1999 until 2010, fatal ... 237% increase in fatal overdoses in male populations.(1) , The proportion of women using ...
(Date:2/27/2017)... ... ... Elisa Guajardo Carothers is not your typical author. She went from working as a movie ... writes about God, when she isn’t swimming as a performing mermaid. , Her book isn’t ... Satan),” she offers a comedic look at the dysfunctions of God’s family, before Lucifer was ...
(Date:2/27/2017)... ... February 27, 2017 , ... This webinar , ... as a tool to characterize particle size distributions in the field of geoscience ... and novel scientific findings. It describes methods of optimized and standardized sample collection, ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... POUGHKEEPSIE, N. ... ) has disclosed that despite scientific studies, the Center for Disease Control ( CDC ... Lyme disease . Kenneth B. Liegner, M.D. has compiled into a single volume ...
(Date:2/27/2017)... ... 2017 , ... Sunshine Coast Health Centre (SCHC), one of ... https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition of a registered massage ... commitment to innovation in drug rehab and alcohol treatment strategies beyond a "punishment" ...
Breaking Medicine News(10 mins):